Please login or register first to view this content.
Cardiovascular Disease Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Oral Semaglutide NDAs Seeking T2D Indication, CV Risk Reduction
Rivaroxaban Reduces Risk of Stroke, Post-Stroke Mortality in Real-World Study
‘Potentially Concerning’ Signal Identified in Long-Term Follow-up Data Involving Paclitaxel-Coated Products
Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions
Adding Bempedoic Acid to Statin Therapy Reduces LDL Cholesterol
FDA Approves New Valsartan Product Following Major Recall
Prasugrel Compared With Ticagrelor in Patients With ACS Undergoing PCI
Does Age Impact Alirocumab Efficacy in Patients With HeFH?
Diuretic Use Differences Examined in HFrEF Patients Treated With Sacubitril/Valsartan, Enalapril
Ready-to-Use Presentation of Platelet Aggregation Inhibitor Eptifibatide Now Available
Authorized Generic of Tekturna Now Available
Prognostic Bleeding Risk Models Developed for Aspirin Use
Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
Eating Nuts Tied to Reduced CVD Incidence, Death in T2DM Patients
FDA Warns About ‘Miracle’ Young Blood Infusion Treatments
Discharge Opioid Rx for Heart Disease Patients May Impact Follow-Up
Artificially Sweetened Drinks Linked to Stroke After Menopause
Linagliptin Non-Inferior to Glimepiride in Long-Term Cardiovascular Outcome Study
